WellDoc
Digital health company revolutionizing chronic disease management.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor investor investor investor investor | €0.0 | round | |
$7.5m | Series B | ||
| Total Funding | 000k | ||
Related Content
Welldoc operates in the digital health sector, focusing on chronic care management through its flagship product, BlueStar. BlueStar is an FDA-cleared Software as a Medical Device (SaMD) designed to manage type 1 and type 2 diabetes. The platform leverages scientific rigor and real-world studies to provide personalized health activation and support adherence to treatment plans. Welldoc collaborates with various partners, including Dexcom and Redox, to enhance its offerings and optimize provider interactions. The company serves a diverse client base, including employers, health plans, health systems, and individual users. Its business model revolves around providing digital health solutions that are reimbursed by CMS for remote patient monitoring. Welldoc generates revenue through subscriptions and partnerships, aiming to empower individuals to take control of their health through precise and personalized care strategies.
Keywords: digital health, chronic care, diabetes management, FDA-cleared, personalized care, remote monitoring, SaMD, BlueStar, health plans, scientific rigor.